Trials / Recruiting
RecruitingNCT06805994
Administering NMT to Reestablish Infant Nasal Microbiome Diversity Following Intranasal Mupirocin Treatment
Parent-to-Child Nasal Microbiota Transplant to Reestablish Nasal Microbiome Diversity After Intranasal Mupirocin Treatment of Children With Staphylococcus Aureus Nasal Colonization
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 175 (estimated)
- Sponsor
- Johns Hopkins University · Academic / Other
- Sex
- All
- Age
- 0 Years – 60 Years
- Healthy volunteers
- Accepted
Summary
This protocol aims to evaluate how NMT affects pediatric nasal microbiome diversity following intranasal mupirocin treatment
Detailed description
This parent-to-child NMT study will test the effect of an anterior nares, or nasal, microbiota transplant (NMT) on seeding, engraftment, and diversity of the neonatal microbiome following nasal decolonization for S. aureus. Infants admitted to the Johns Hopkins Neonatal Intensive Care Unit (NICU) will be screened and parents will be approached for enrollment in the study. After consent and baseline screening of parents and infants, eligible infants will undergo an NMT.
Conditions
- Staphylococcal Aureus Infection
- Microbial Colonization
- Pediatric Infection
- S. Aureus Colonization
- Microbial Transplant
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Nasal Microbiota Transplant (NMT) | nasal microbiota transplant |
| BIOLOGICAL | Placebo | Placebo sterile swab |
Timeline
- Start date
- 2025-08-27
- Primary completion
- 2027-09-01
- Completion
- 2028-01-01
- First posted
- 2025-02-03
- Last updated
- 2025-09-04
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06805994. Inclusion in this directory is not an endorsement.